Core Insights - Purple Biotech is advancing NT219 in combination with EGFR antibody cetuximab into a Phase 2 study for head and neck cancer [1][3] - The U.S. Patent and Trademark Office has issued a patent for NT219, enhancing its protection in major markets [1][4] - The head and neck cancer treatment market is projected to reach $5 billion by 2030 [3] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance [5] - The company's oncology pipeline includes NT219, CM24, and CAPTN-3, with NT219 being a dual inhibitor targeting IRS1/2 and STAT3 [5] - CM24 has shown promise in a Phase 2 study for pancreatic ductal adenocarcinoma, demonstrating improvement across efficacy endpoints [5] Intellectual Property - The newly issued patent for NT219 in combination with cetuximab completes geographic patent protection in the U.S., Europe, China, and Japan [4] - Purple Biotech's intellectual property portfolio includes a previously issued patent covering NT219 with small molecule EGFR inhibitors [4]

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux) The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of the Head and Neck Cancer Program REHOVOT, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NA ...

Core Insights - Purple Biotech Ltd. has entered into a Research Collaboration Agreement with the Icahn School of Medicine at Mount Sinai to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) using its CAPTN-3 multi-specific engagers, aiming to enhance tumor-specific immunity against various cancer types [1][6]. Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies that address tumor immune evasion and drug resistance, with a pipeline that includes CM24, NT219, and CAPTN-3 [5]. - CM24 is a humanized monoclonal antibody targeting CEACAM1, which plays a role in tumor immune evasion, and has shown efficacy in a Phase 2 study for pancreatic ductal adenocarcinoma [5]. - NT219 is a dual inhibitor targeting IRS1/2 and STAT3, demonstrating anti-tumor activity in combination with cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck [5]. Research Collaboration - The collaboration with the Icahn School of Medicine aims to deepen the understanding of the mechanisms of action for CAPTN-3 in preparation for human clinical studies [2]. - Dr. Amir Horowitz, the Principal Investigator, is an expert in immunoregulation and has identified the HLA-E/NKG2A axis as a significant inhibitory checkpoint pathway in solid tumors [2][3]. - The study will focus on how CAPTN-3 antibodies alter T and NK cell activation within the TME, particularly regarding HLA-E/NKG2A interactions [3]. CAPTN-3 Mechanism - CAPTN-3 is designed to promote innate-like antitumor functions by NK and CD8 T cells through conditional activation of the anti-CD3 arm at the TME and blockade of NKG2A [6][7]. - The technology aims to unleash both innate and adaptive immune systems to mount an optimal anti-tumoral immune response, potentially improving responses in resistant cancer patients [7].

REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 472,668 of the Company’s American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS. H.C. Wainwright & Co. acted as the exc ...

Purple Biotech (PPBT) , a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead candidate, CM24, for treating pancreatic ductal adenocarcinoma (“PDAC”) patients. CM24 is a humanized monoclonal antibody that blocks CEACAM1, supporting tumor immune evasion and survival through multiple pathways.Purple Biotech states that treatment with CM24 in the phase II study demonstrated a clear and consistent improvement across all efficacy endpoints. A potential patient su ...

On Monday, Purple Biotech Ltd PPBT reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC).Purple Biotech stock is trading higher with a strong session volume of 9.7 million, compared to an average volume of 48.73K as per data from Benzinga Pro.The Phase 2 study evaluated CM24 in combination with Bristol Myers Squibb & Co’s BMY immune checkpoint inhibitor nivolu ...

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2024 REHOVOT, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class th ...

Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24 Definition of serum biomarkers for patient selection offers a substantial advantage in developing treatments for cancer CM24, a CEACAM1 inhibitor, is currently being evaluated in a Phase 2 randomized pancreatic cancer study, with topline results expected in Q4 of 2024  REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple Biotech ...

High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients (HR=0.1 and prolongation of 4.1 months in median OS, p value 0.01, for the combination), which support the CM24/nivolumab combined treatment. Improved OS is demonstrated for patients with serum neutrophil extracellular trap (NET) marker myeloperoxidase (MPO) (HR=0.38 and prolongation of 3.3 months in ...

Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the combination of CM24+nivolumab and NAL-IRI/5FU/LV chemotherapy cohort Evaluating expansion of CM24 clinical program to a biomarker driven study in additional indications based on CEACAM1 novel oncology target on Neutrophil E ...